Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ENLV)

Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

GlobeNewswire 8 days ago

Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25

GlobeNewswire 12 days ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

GlobeNewswire June 17, 2024

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

GlobeNewswire June 3, 2024

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

GlobeNewswire May 29, 2024

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

GlobeNewswire May 28, 2024

Enlivex CEO Issues Letter to Shareholders - Perspectives on Recent Events

GlobeNewswire April 29, 2024

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra(TM) in Patients with Knee Osteoarthritis

GlobeNewswire April 22, 2024

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

GlobeNewswire April 16, 2024
View More News ››

Opinion & Analysis (NDAQ:ENLV)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ENLV)

BUY BUY BUY BUY BUY

Whytestock is right on the news this thing alocentra gonna be first and only fda approuved
Nibinator - 6 days ago

Enlivex Announces the Dosing of the First Patient in a Rando

BREAKING NEWS: $ENLV Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating...
whytestocks - 8 days ago

Enlivex CEO Issues Letter to Shareholders - Perspectives on

News; $ENLV Enlivex CEO Issues Letter to Shareholders - Perspectives on Recent EventsNes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) ...
whytestocks - April 29, 2024

H.C. Wainwright Article on Enlivex

Worth the read for investors and potential investors, https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-a-buy-rating-on-enlivex...
HariboSpeedPeak - July 21, 2022

Price Target $15

Bio Blast Pharma Ltd (NASDAQ:ORPN) had its "buy" rating reaffirmed by analysts at Roth Capital (     ). They now have...
Twistedsteel74 - June 13, 2016

Anyone else out there on these?

Looks to be some good movement upwards here, guessing must be some news coming as financials weren't stellar.
Twistedsteel74 - May 26, 2016
View more Bullboard ››

Western Exploration Inc

Western Exploration Inc

Western Exploration Inc. is focused on gold and silver discoveries in Northern Nevada. The Company is engaged in the business ...
View More »